NCT00576173 2010-04-28
An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients
Johnson & Johnson Taiwan Ltd
Phase 4 Completed